• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Enveric Biosciences

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
Today 16:05 EST
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Broad Range of Patent Issuances
November 04, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
October 15, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
September 26, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 25, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
August 13, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
August 12, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
July 25, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
July 15, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Patent Granted for Drug Candidate
July 10, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
June 25, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in BIO International Convention 2024
May 30, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
May 15, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
May 14, 2024
From Enveric Biosciences
Via Business Wire
Tickers CSE:MBIO ENVB
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
May 08, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
March 26, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease
March 19, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets
March 12, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
February 29, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property
February 23, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
February 21, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
January 03, 2024
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market
December 29, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series
December 28, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
December 27, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences to Participate in Biotech Showcase 2024 During “J.P. Morgan Week 2024”
December 20, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds
December 05, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
November 29, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry
November 27, 2023
From Enveric Biosciences
Via Business Wire
Tickers ENVB
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap